Friday, December 31, 2021 2:38:58 PM
exwannabe,
Cognate started being prepped for expanded capacity when new clean rooms started arriving in 2015 after good news was turned into bad according to NWBO. In 2021 Cognate suddenly anticipated a need to double manufacturing capacity ASAP after DCVax-L Phase 3 data lock and a likely NDA early look at anticipated demand for US and Canada with potential rGBM demand added in because of rGBM endpoint changes by NWBO. Then Charles Rivers Labs took over one month later and looked to expand even further around the time talk about SOC and Project Orbis was picking up.
Yes we have been talking about manufacturing for a while but nothing all that serious about Merck until Roger Perlmutter was seen at an NWBO presentation and then Dr Duffy joined NWBO during the time they would have been working on the revised SAP which was not 6 years ago. The correlation seems to be endpoint changes, SOC and Project Orbis talk that created an anticipatory demand to be prepared. Not hard to see this if looking in the right direction. Best wishes.
Cognate started being prepped for expanded capacity when new clean rooms started arriving in 2015 after good news was turned into bad according to NWBO. In 2021 Cognate suddenly anticipated a need to double manufacturing capacity ASAP after DCVax-L Phase 3 data lock and a likely NDA early look at anticipated demand for US and Canada with potential rGBM demand added in because of rGBM endpoint changes by NWBO. Then Charles Rivers Labs took over one month later and looked to expand even further around the time talk about SOC and Project Orbis was picking up.
Yes we have been talking about manufacturing for a while but nothing all that serious about Merck until Roger Perlmutter was seen at an NWBO presentation and then Dr Duffy joined NWBO during the time they would have been working on the revised SAP which was not 6 years ago. The correlation seems to be endpoint changes, SOC and Project Orbis talk that created an anticipatory demand to be prepared. Not hard to see this if looking in the right direction. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
